<DOC>
	<DOC>NCT02269852</DOC>
	<brief_summary>The purpose of this study is to evaluate the immunogenicity and safety of Northern hemisphere 2013-2014 seasonal trivalent inactivated influenza vaccine in 60 healthy infants aged 6-35 months old, 60 healthy adults aged 18-60 years old, and 60 healthy seniors aged &gt; 60 years.</brief_summary>
	<brief_title>The Immunogenicity and Safety of 2013-2014 Seasonal Trivalent Influenza Vaccine</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>For adults and seniors: Healthy adults aged 1860 years old, and healthy seniors aged &gt; 60 years old; Without vaccination history of seasonal split influenza vaccine in the recent 3 years No traveling plan during the study period of this trial; Be able to understand and sign the informed consent; Allergic to egg products or any ingredient of the study vaccine; Fever, influenza or acute illness on the vaccination day; Acute stage of chronic illness; Malignant tumor; Immunodeficiency, includes HIV infection; GuillainBarre syndrome; Administration of live attenuated vaccine within the previous 14 days; Administration of subunit or inactivated vaccine within the previous 7 days; Planned to participate in any other clinical trial of drug or vaccine during this study; Received immunesuppressive treatment within the previous month, or planned for such treatment during this study; Pregnant, or planning pregnancy; Axillary temperature &gt; 37.0℃; Any other factors that, in the judgment of the investigator, is unsuitable for this study; For infants: Healthy male or female aged between 6 and 35 months; Fullterm birth, birth weight 2,500 grams or more; Provided birth certification or vaccination card Parent or legal guardian is able to understand and sign the informed consent; Received seasonal influenza vaccine after June 30, 2012; Acute infection within the previous week; Allergy history, or allergic to any ingredient of the study vaccine, such as egg; History of serious adverse reaction (SAR) to vaccine; Autoimmune disease or immune deficiency, or administration of immunosuppressive therapy, cell toxic therapy, or inhaled corticosteroid within the previous 6 months; Congenital malformations, developmental disorder or serious chronic disease; Unstable condition of asthma and administration of corticosteroid in the most recent two years; Coagulation abnormalities or disorders; History/ family history of infantile convulsion, epilepsy, cerebropathy, or mental disease; Without spleen; Severe neurological diseases, such as GuillainBarre syndrome; Administration of blood products or investigational drug within the previous month; Administration of live attenuated vaccine within the previous 14 days; Administration of subunit or inactivated vaccine within the previous 7 days; Received treatment for allergy within the previous 14 days; ongoing antituberculosis therapy; Axillary temperature &gt; 37.0℃ immediately before vaccination; any other factors that, in the judgment of the investigator, is unsuitable for this study;</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>seasonal trivalent inactivated influenza vaccine</keyword>
	<keyword>immunogenicity</keyword>
	<keyword>safety</keyword>
	<keyword>cross-reactivity</keyword>
	<keyword>Northern hemisphere 2013-2014 formulation</keyword>
</DOC>